Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer Stage IV
Breast Cancer, Stage IIIB
Breast Cancer Stage IIIA

Interventions: Drug: 1% Glycated Chitosan
Drug: Standard of Care
Device: Photothermal Laser
Drug: Placebo
Drug: Cyclophosphamide

First Posted Date: 2017-06-28

Last Posted Date: 2018-02-23

Lead Sponsor: Eske Corporation S.A.C

Target Recruit Count: 18

Registration Number: NCT03202446

Locations: 🇵🇪
Clinica Ricardo Palma, Lima, Peru
🇵🇪
Hospital Nacional Arzobispo Loayza, Lima, Peru
🇵🇪
Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru

and more 1 locations

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3

Completed

Conditions: Amyloidosis

Interventions: Drug: Cyclophosphamide
Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone, 40 mg

First Posted Date: 2017-06-28

Last Posted Date: 2025-01-07

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 416

Registration Number: NCT03201965

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 138 locations

Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

Phase 2

Completed

Conditions: To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients

Interventions: Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil

First Posted Date: 2017-06-27

Last Posted Date: 2017-06-28

Lead Sponsor: Chitwan Medical College

Target Recruit Count: 49

Registration Number: NCT03200002

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1

Withdrawn

Conditions: Urothelial Carcinoma

Interventions: Biological: avelumab
Biological: bevacizumab
Drug: capecitabine
Drug: cisplatin
Drug: cyclophosphamide
Drug: 5Fluorouracil (5-FU)
Drug: fulvestrant
Drug: leucovorin
Drug: nab-paclitaxel
Drug: Lovaza
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-011
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Biological: haNK

First Posted Date: 2017-06-23

Last Posted Date: 2021-03-18

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03197571

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Phase 1

Withdrawn

Conditions: Ovarian Cancer

Interventions: Biological: Avelumab
Biological: Bevacizumab
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: 5-fluorouracil
Drug: Fulvestrant
Drug: Leucovorin
Drug: Paclitaxel
Drug: omega-3 acid ethyl esters
Drug: Oxaliplatin
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6301
Biological: haNK®

First Posted Date: 2017-06-23

Last Posted Date: 2021-03-18

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03197584

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Phase 3

Completed

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Drug: Placebo
Drug: Nab-paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Pegfilgrastim

First Posted Date: 2017-06-23

Last Posted Date: 2023-10-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 333

Registration Number: NCT03197935

Locations: 🇩🇪
Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany
🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom
🇦🇺
Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia

and more 65 locations

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia in Remission
Adult Acute Lymphoblastic Leukemia in Complete Remission
Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
Chronic Myelomonocytic Leukemia in Remission
Graft Versus Host Disease
Severe Aplastic Anemia
Hodgkin Lymphoma
Minimal Residual Disease
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan Hydrochloride
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-06-20

Last Posted Date: 2024-05-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 35

Registration Number: NCT03192397

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Phase 1

Withdrawn

Conditions: Myeloma Multiple

Interventions: Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Pembrolizumab

First Posted Date: 2017-06-19

Last Posted Date: 2017-08-24

Lead Sponsor: University of Leeds

Registration Number: NCT03191981

Locations: 🇬🇧
University College Hospital, London, United Kingdom
🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, United Kingdom

and more 1 locations

Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer

Phase 2

Completed

Conditions: Endometrial Cancer
Cervical Cancer
Uterine Cancer

Interventions: Drug: Pembrolizumab
Radiation: Radiation
Drug: Vitamin D
Drug: Aspirin
Drug: Lansoprazole
Drug: Cyclophosphamide
Dietary Supplement: Curcumin

First Posted Date: 2017-06-19

Last Posted Date: 2021-09-08

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 43

Registration Number: NCT03192059

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
University Hospital Antwerp, Antwerp, Belgium
🇧🇪
University Hospital Gent, Gent, Belgium

and more 1 locations

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Gastric Cancer
Colon Cancer
Rectal Cancer
Gastrointestinal Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Anti-KRAS G12V mTCR PBL
Drug: Aldesleukin

First Posted Date: 2017-06-19

Last Posted Date: 2024-12-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT03190941

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy